The acquisition brings three established small-molecule drug substance facilities into Siegfried’s global network
Net sales reached CHF 1,327.8 million, up 2.6% year-on-year in Swiss francs, or 4.3% at constant exchange rates
The deal brings three high-quality small-molecule drug substance sites into Siegfried’s portfolio
Siegfried plans to grow its exclusive synthesis business in the US by optimizing controlled substance capacity at the Wilmington and nearby Pennsville sites
The new site enables end-to-end production of viral vector gene therapies
The new facility significantly increases Siegfried’s R&D capacity to drive development excellence and further growth
Subscribe To Our Newsletter & Stay Updated
